Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

08-03-2017 | Uterine cancer | Book chapter | Article

18. Endometrial Cancer

Authors: Allison L. Goetsch, Dana Kimelman, Teresa K. Woodruff

Publisher: Springer International Publishing

Login to get access

Abstract

Gynecological cancers are more prevalent in postmenopausal women. In patients younger than 40 years old, the incidence is also significant. As fertility preservation is a big issue for cancer survivors, it is necessary to realize that treatment decisions are being made thinking on future fertility. When we talk about oncofertility, it is extremely important to take into account that each cancer has different effect on fertility, because of the disease and also because of its treatment. Cancer treatment includes surgery, hormonal treatment, chemotherapy, radiotherapy, and others. This chapter reviews endometrial cancer diagnosis, risk factors, treatments, and fertility preservation options.
Literature
1.
Landrum LMZ, Walker JL. Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In: Di Saia JDC, Creasman WT, editors. Clinical gynecologic oncology. 18th ed. St. Louis: Elsevier; 2012. p. 121–39.CrossRef
2.
Gressel GM, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet: Off Organ Int Federat Gynaecol Obstet. 2015;131(3):234–9.CrossRef
3.
van Gent MD, Nicolae-Cristea AR, de Kroon CD, Osse EM, Kagie MJ, Trimbos JB, et al. Exploring morphologic and molecular aspects of endometrial cancer under progesterone treatment in the context of fertility preservation. Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc. 2016;26(3):483–90.CrossRef
4.
Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, et al. European society of gynecological oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2015;25(7):1258–65.CrossRef
5.
Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.CrossRefPubMed
6.
Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. J Obstet Gynaecol: J Instit Obstet Gynaecol. 2011;31(1):13–7.CrossRef
7.
Hale GE, Hughes CL, Cline JM. Endometrial cancer: hormonal factors, the perimenopausal "window of risk," and isoflavones. J Clin Endocrinol Metab. 2002;87(1):3–15.PubMed
8.
Chlebowski RT, Anderson GL. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids. 2014;90:53–9.CrossRefPubMedPubMedCentral
9.
Shai A, Segev Y, Narod SA. Genetics of endometrial cancer. Familial Cancer. 2014;13(3):499–505.CrossRefPubMed
10.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103(2):535–40.CrossRefPubMed
11.
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecol Oncol Group Study Cancer. 1987;60(8 Suppl):2035–41.
12.
ACOG Committee Opinion No 440. The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Obstet Gynecol. 2009;114(2 Pt 1):409–11.
13.
Xu WH, Xiang YB, Zheng W, Zhang X, Ruan ZX, Cheng JR, et al. Weight history and risk of endometrial cancer among Chinese women. Int J Epidemiol. 2006;35(1):159–66.CrossRefPubMed
14.
Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv. 2012;67(11):726–33.CrossRefPubMed
15.
Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996;41(5 Suppl):419–27.PubMed
16.
Collaborative Group on Epidemiological Studies on Endometrial Cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061–70.
17.
Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88–105.CrossRefPubMed
18.
Practice Bulletin No 149. Endometrial cancer. Obstet Gynecol. 2015;125(4):1006–26.CrossRef
19.
Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, et al. Management of endometrial precancers. Obstet Gynecol. 2012;120(5):1160–75.PubMedPubMedCentral
20.
Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78.CrossRefPubMed
21.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11–30.CrossRefPubMed
22.
Vitobello D, Siesto G, Bulletti C, Accardi A, Levi Setti PE. Gynecological fertility-sparing surgery. Placenta. 2011;32(Suppl 3):S224–31.CrossRefPubMed
23.
Martinez M, Rabadan S, Domingo J, Cobo A, Pellicer A, Garcia-Velasco JA. Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. Reprod BioMed Online. 2014;29(6):722–8.CrossRefPubMed
24.
Rackow BW, Arici A. Endometrial cancer and fertility. Curr Opin Obstet Gynecol. 2006;18(3):245–52.CrossRefPubMed
25.
Yarali H. A successful pregnancy after intracytoplasmic sperm injection and embryo transfer in a patient with endometrial cancer who was treated conservatively. Fertil Steril. 2004;81(1):214–6.CrossRefPubMed
26.
Jantarasaengaram S, Praditphol N, Tansathit T, Vipupinyo C, Vairojanavong K. Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer. Ultrasound Obstet Gynecol: Off J Int Soc Ultrasound Obstet Gynecol. 2014;43(5):569–74.CrossRef
27.
Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(2):249–52.CrossRef
28.
Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(6):1068–73.CrossRef
29.
Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95(1):133–8.CrossRefPubMed
30.
Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol. 2008;111(2 Suppl):S101–4.CrossRefPubMed
31.
Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93(4):1286–9.CrossRefPubMed
32.
Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol: Off J Int Soc Gynecol Endocrinol. 2009;25(10):683–91.CrossRef
33.
Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, et al. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016;143(3):466–71.CrossRefPubMed
34.
Gurgan T, Bozdag G, Demirol A, Ayhan A. Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review. Reprod BioMed Online. 2007;15(5):561–5.CrossRefPubMed
35.
Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol. 2003;91(3):569–72.CrossRefPubMed
36.
Demirol A, Bahce M, Ayhan A, Gurgan T. Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer. Reprod BioMed Online. 2005;10(6):770–3.CrossRefPubMed
37.
Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88(6):1562–7.CrossRefPubMed
38.
Bozdag G, Yarali H, Polat M, Esinler I, Tiras B, Ayhan A. ICSI outcome following conservative fertility sparing management of endometrial cancer. Reprod BioMed Online. 2009;18(3):416–20.CrossRefPubMed
39.
Sodano M, Bogliatto F, Morero S, Mosso L, Torchio B, Leidi L. Case report: Successful IVF programme after conservatively treated endometrial cancer. Reprod BioMed Online. 2009;18(4):578–81.CrossRefPubMed
40.
Chao AS, Chao A, Wang CJ, Lai CH, Wang HS. Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: case series and literature review. Taiwanese J Obstet Gynecol. 2011;50(1):62–6.CrossRefPubMed
41.
Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2012;207(4):266. e1–12CrossRefPubMed
42.
Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril. 2007;88(3):657–64.CrossRefPubMed
43.
Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG: Int J Obstet Gynaecol. 2005;112(3):317–20.CrossRef
44.
Leblanc E, Narducci F, Ferron G, Querleu D. Indications and teaching of fertility preservation in the surgical management of gynecologic malignancies: European perspective. Gynecol Oncol. 2009;114(2 Suppl):S32–6.CrossRefPubMed